Accropeutics’ Oral TYK2 Inhibitor AC-201 Cleared for Vitiligo Phase II/III

Accro Bioscience (Suzhou) Limited, better known as Accropeutics, announced on Sept 8, 2026 that its drug candidate AC-201, a novel oral small-molecule TYK2/JAK1 inhibitor, has received approval from China’s National Medical Products Administration (NMPA) to conduct Phase II/III clinical trials for the treatment of non-segmental vitiligo.

Program Snapshot

Clinical Context

Non-segmental vitiligo is the most common depigmenting disorder, affecting roughly 0.5–2% of the global population, in which autoimmune destruction of melanocytes produces progressive white patches on the skin. The disease is driven by interferon-γ signaling through the JAK–STAT pathway, with TYK2 and JAK1 acting as the principal kinases transducing the cytokine signal that recruits cytotoxic T cells against pigment cells. AC-201 is engineered for allosteric selectivity: it binds the pseudokinase domain (JH2) of TYK2/JAK1 — the regulatory domain distinct from the active catalytic site — enabling potent inhibition of the disease-driving kinases while sparing the JAK2/JAK2 pathway associated with hematologic toxicity, including anemia and thrombocytopenia. This JH2-binding, JAK2-sparing profile mirrors the design logic of deucravacitinib, the first approved allosteric TYK2 inhibitor, but extends it to dual TYK2/JAK1 coverage in an oral formulation. Critically, an oral systemic therapy addresses a central limitation in vitiligo care: topical JAK inhibitors such as ruxolitinib cream must be applied to lesions twice daily — a burden that drives poor adherence in widespread disease — whereas an oral option could practically treat extensive depigmentation.

Market Impact Analysis

The Phase II/III green light places AC-201 among the first wave of oral systemic candidates pursuing registration-track vitiligo trials in China, a market with high unmet need and no approved oral repigmentation therapy. Because vitiligo carries profound psychosocial impact despite low mortality, patient demand for effective systemic options is durable, and success would anchor a franchise spanning the other autoimmune indications for which the molecule is being developed.

The commercial pathway is already consolidated: Fosun Pharmaceutical Industrial, a subsidiary of Fosun Pharma (SHA: 600196, HKG: 2196), acquired AC-201’s rights in Mainland China, Hong Kong, and Macao in August 2025 for RMB 156 million. That structure — a capital-light biotech discovering assets while a large pharma funds and runs Greater China development — is a now-standard Chinese licensing model, and the trial advancement likely carries milestone implications for Accropeutics under the deal terms. The NMPA clearance also retrospectively validates the RMB 156 million valuation Fosun committed before pivotal-stage data existed — an early-stage bet on the JH2-selectivity concept.

Competitively, AC-201 must distinguish itself against topical standards of care and future oral entrants in the TYK2/JAK class. Its claimed differentiation — dual TYK2/JAK1 potency with JAK2 sparing — targets the classic weakness of systemic JAK inhibitors: class-wide safety concerns that have constrained their use in chronic, non-fatal indications where the risk-benefit bar is high.

Forward-Looking Statement

Fosun Pharma and its partners are expected to initiate the NMPA-authorized Phase II/III program in non-segmental vitiligo, with dosing, enrollment, and repigmentation endpoints to be detailed in trial registrations. Investors will watch for first-patient-in announcements, milestone disclosures under the 2025 licensing agreement, and any expansion of AC-201 into additional autoimmune indications. Progression toward registration remains contingent on pivotal efficacy and on the JAK2-sparing safety profile holding up in humans, barring competitive or regulatory shifts in systemic vitiligo therapy.-Fineline Info & Tech